Literature DB >> 34783257

Safety levels of systemic IL-12 induced by cDNA expression as a cancer therapeutic.

Constanza Savid-Frontera1, Maria E Viano1, Natalia S Baez1, Della Reynolds2, Mariana Matellon1, Howard A Young2, Maria C Rodriguez-Galan1.   

Abstract

Aim: The aim of this work is to utilize a gene expression procedure to safely express systemic IL-12 and evaluate its effects in mouse tumor models. Materials & methods: Secondary lymphoid organs and tumors from EL4 and B16 tumor-bearing mice were analyzed by supervised and unsupervised methods.
Results: IL-12 cDNA induced systemic IL-12 protein levels lower than the tolerated dose in patients. Control of tumor growth was observed in subcutaneous B16 and EL4 tumors. Systemic IL-12 expression induced a higher frequency of both total tumor-infiltrated CD45+ cells and proliferative IFN-γ+CD8+ T cells along with a lower frequency of CD4+FOXP3+ and CD11b+Gr-1+ cells.
Conclusion: This approach characterizes the systemic effects of IL-12, helping to improve treatment of metastases or solid tumors.

Entities:  

Keywords:  B16; CD8+ T cells; EL4; IFN-γ; cancer; hydrodynamic injection; immunotherapy; secondary lymphoid organs; systemic IL-12; tumor microenvironment

Mesh:

Substances:

Year:  2021        PMID: 34783257      PMCID: PMC8739399          DOI: 10.2217/imt-2021-0080

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  59 in total

1.  IFN-gamma-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12.

Authors:  S Nakamura; T Otani; Y Ijiri; R Motoda; M Kurimoto; K Orita
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

2.  A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Premal H Thaker; William E Brady; Heather A Lankes; Kunle Odunsi; William H Bradley; Kathleen N Moore; Carolyn Y Muller; Khursheed Anwer; Russell J Schilder; Ronald D Alvarez; Paula M Fracasso
Journal:  Gynecol Oncol       Date:  2017-08-10       Impact factor: 5.482

3.  Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy.

Authors:  Irma Airoldi; Emma Di Carlo; Claudia Cocco; Carlo Sorrentino; Franco Fais; Michele Cilli; Tommaso D'Antuono; Mario Paolo Colombo; Mario Paulo Colombo; Vito Pistoia
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

4.  IL-12-induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses.

Authors:  L Meyaard; E Hovenkamp; S A Otto; F Miedema
Journal:  J Immunol       Date:  1996-04-15       Impact factor: 5.422

5.  Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses.

Authors:  A H Rook; G S Wood; E K Yoo; R Elenitsas; D M Kao; M L Sherman; W K Witmer; K A Rockwell; R B Shane; S R Lessin; E C Vonderheid
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

6.  CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes.

Authors:  Rinke Bos; Linda A Sherman
Journal:  Cancer Res       Date:  2010-10-12       Impact factor: 12.701

7.  Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice.

Authors:  P Charoensit; S Kawakami; Y Higuchi; F Yamashita; M Hashida
Journal:  Cancer Gene Ther       Date:  2010-04-23       Impact factor: 5.987

8.  Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity.

Authors:  Maria Cecilia Rodriguez-Galan; Della Reynolds; Silvia G Correa; Pablo Iribarren; Morihiro Watanabe; Howard A Young
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

9.  Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

Authors:  Adil I Daud; Ronald C DeConti; Stephanie Andrews; Patricia Urbas; Adam I Riker; Vernon K Sondak; Pamela N Munster; Daniel M Sullivan; Kenneth E Ugen; Jane L Messina; Richard Heller
Journal:  J Clin Oncol       Date:  2008-11-24       Impact factor: 44.544

10.  Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.

Authors:  M J Robertson; C Cameron; M B Atkins; M S Gordon; M T Lotze; M L Sherman; J Ritz
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.